Study of a three-drug combo for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have advanced liver cancer that cannot be treated with surgery or local therapies.
- Your tumor must have a specific marker called FGF19 overexpression, confirmed by a tissue sample.
- You must have at least one tumor that can be measured on a scan.
- You must be in generally good health (ECOG score 0 or 1).
- Your liver and kidney function must meet certain blood test standards.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
Hear when a new Carcinoma, Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.